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Valorization 
Social relevance
In 2010, approximately 33.5 million people were suffering from atrial fibrillation (AF), 
defining this arrhythmia as the most common rhythm disturbance in clinical practice1. 
The burden of AF in Dutch general population amounts to 1.6% and up to 1.8% in the 
European Union overall2. The major risk factors for AF are age, hypertension, heart failure, 
coronary artery disease, valvular heart disease, obesity, diabetes mellitus, and chronic 
kidney disease. Taking into account that actual demographic trends suggest a significant 
increase in the average age of the European Union population it is estimated that the 
burden of AF is going to be doubled by the year of 20602.
Atrial fibrillation is recognized as an independent predictor of mortality and is associated 
with many disabling diseases including stroke and heart failure3. It is estimated that one 
in five strokes is a direct consequence of AF. In addition, patients with AF are more often 
hospitalized and have a significantly lower quality of life4, 5. It is important to note that AF 
is a chronic disease that needs permanent surveillance and very often constant treatment. 
Considering the above, it is clear that AF is a disease that causes a significant burden for 
our health care system, which is going to rise over time.
Current treatment options 
Current evidence-based treatment strategies include interventions that aim to restore 
and maintain sinus rhythm, also named ‘rhythm control’, or interventions whose main 
goal is to prevent the development of AF-related complications such as heart failure (‘rate 
control’) or the prevention thromboembolic events6.
Rhythm control includes drug treatments administered either acutely for pharmacological 
cardioversion (restoration of sinus rhythm) or chronically for sinus rhythm maintenance. 
Electrical cardioversion is also used for acute sinus rhythm restoration. Various 
interventional and surgical ablation procedures that produce scar tissue in the atria and 
therefore prevent the propagation of fibrillation waves are also recognized as rhythm 
control treatment strategies6.
The development or exacerbation of heart failure as a consequence of AF is mainly related 
to the high and irregular ventricular activation rates7. Therefore, ventricular protection in 
AF patients requires the maintenance of ventricular rate within a more normal range. 
This treatment strategy is also known as ‘rate control’ and includes mainly chronic drug 
administration to inhibit AV node conduction and in some cases combinations of ablation 
procedures and pacemaker implantation6
The prevention of the thromboembolic events includes the use of various anticoagulation 
medication8. In some cases, different interventional or surgical techniques can be also 
used to close or to remove the left atrial appendage which is the most frequent location 
of emboli9, 10.
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Although at the first glance the possibilities to treat AF are plentiful, their success rate and 
especially long-term results are still unsatisfactory. In addition, many of the mentioned 
treatments are often associated with numerous serious complications and a further 
reduction in the quality of life of patients with AF.
Cardioversions i.e. restoration of sinus rhythm either by means of pharmacological or 
electrical cardioversions are highly successful in directly restoring sinus rhythm, but AF 
recurrence is very frequent11. For sinus rhythm maintenance different antiarrhythmic 
drugs are used, but prolonged treatment with available antiarrhythmic drugs are often 
associated with various cardiac and extracardiac side effects12. This underscored the 
need for more specific antiarrhythmic drugs that are more atrial-selective and therefore 
produce fewer side-effects.
Ablation strategies are recommended as the second line of treatment for symptomatic 
paroxysmal, persistent, and probably long-standing persistent AF patients in which 
pharmacological SR maintenance was not achievable6. Ablation strategies have a better 
success rate in maintaining SR, but there is no proof that successful ablation would reduce 
hospitalization or enable discontinuation of anticoagulation therapy. Importantly, the 
ablation strategies are associated sometimes with life-threatening complications such as 
death in <0.2% or periprocedural stroke in <1%, while clinically undetectable strokes can 
be demonstrated in up to 20% of cases6, 13. Together with other less severe complications 
different ablations strategies should be employed with caution and used only in selected 
patients.
Prevention of thromboembolic complications such as stroke is mainly achieved with 
the chronic use of anticoagulation drugs14. The most common side-effect of long-term 
anticoagulation is an increase in the incidence of bleeding complications, which in 
exceptional cases could lead to severe disability or even death15. It is also important to 
mention that anticoagulation therapy is also associated with the reduction in quality of 
life and increased medical costs16, 17.
The novelty of our research
In the first two experimental chapters of this thesis (Chapter 3 and 4) we have investigated 
two compounds that can be potentially used for the restoration and eventually 
maintenance of the SR in patients with AF. The advantage of both compounds i.e. ranolazine 
and pentamidine analog6 (PA-6), in a first place is the selectivity of the compounds for 
atrial tissue and therefore high safety.
The PA-6 is a newly synthesized compound that inhibits Ik1. A next step in the development 
of this compound would be the confirmation of its safety and efficacy in humans.
On the other hand, ranolazine is already a registered drug to treat chronic angina pectoris.
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We have provided the proof that ranolazine retains its effectiveness and specificity for 
atrial tissue at different stages of AF mediated ‘electrically remodeled’ atria. However, in 
our study, ranolazine was unsuccessful in restoring SR, but clinical data suggest that it is 
effective in a group of patients with a recent onset of AF or postoperative AF18. In addition, 
ranolazine is safe in patients with the structurally altered hearts and therefore can be 
considered as an additional therapy for SR maintenance in patients with reduced left 
ventricular function. Further, because of ranolazine’s good safety properties and present 
approval for long term use, further studies investigating its long term (metabolic) effects 
in AF are warranted.
Trimetazidine (Chapter 6) is also a drug with metabolism-modulating properties that 
we have investigated. To the best of our knowledge, metabolic modulation as a long-
term treatment option for AF has never been investigated before. We have shown that 
trimetazidine abolished increased production of reactive oxygen species, and attenuated 
the hallmarks of structural remodeling observed during AF including cell hypertrophy, 
interstitial fibrosis, and it preserved mitochondrial shape. Achieving this, trimetazidine 
could be used as an adjuvant drug, not only in AF patients, but also in the patients at risk 
for AF. 
We believe that patients with new-onset or paroxysmal AF would benefit most from 
treatment with trimetazidine because it could prevent accumulation of atrial structural 
alterations leading to arrhythmia stabilization. Preservation of atrial function and structure 
as a bridge to permanent rhythm control strategies could increase ablation success rate 
by reducing the complexity of the fibrillation substrate.
